Dr. Sennewald Medizintechnik, Pyrexar's European distribution partner, has brought together an impressive program of clinicians to talk about hyperthermia's role in the treatment of cancer, at this years ESTRO 38 (European Society for Radiotherapy & Oncology). The luncheon symposium titled "Hyperthermia in the age of personalized oncology" will be held Saturday, April 27th, and is open to all ESTRO attendees (space is limited).
Program outline below:
| Introduction | Daniel Zips, UMC Tübingen, Germany |
| Hyperthermia as an immune modulator in multimodal tumor therapies - immune biological rationale | Michael Hader, Ph.D., UMC Erlangen, Germany |
| Integration of Pencil Beam Scanning Proton Therapy and Hyperthermia: The University of Maryland Clinical Experience | Zeljko Vujaskovic MD, University of Maryland, USA |
| Management of locally recurrent Breast Cancers with local hyperthermia and radiotherapy: A systematic review and meta-analysis | Niloy Datta MD, Canton Hospital Aarau, Switzerland |
| Neoadjuvant chemotherapy combined with deep regional hyperthermia as the new standard for the treatment of patients with high-risk soft-tissue sarcomas | Lars Lindner MD, UMC Munich Grosshadern, Germany |
| Hyperthermia and preoperative chemoradiation for organ-preservation in rectal cancer patients | Cihan Gani MD, UMC Tübingen, Germany |
| Discussion and Summary | Stephan Bodis MD, Canton Hospital Aarau, Switzerland |
ABOUT ESTRO
Founded in 1980, ESTRO, the European SocieTy for Radiotherapy & Oncology, is a non-profit and scientific organization that fosters the role of Radiation Oncology to improve patients’ care in the multimodality treatment of cancer. ESTRO 38 is held in Milan, Italy, April 26th - 30th, 2019, at the Milan Convention Center.